

Date: 18/08/2020

FREEDOM OF INFORMATION REQUEST FOI/015327 – Keytruda

What volume of Keytruda (Pembrolizumab) is used for each of the following indications:

Lung Cancer, Renal Cell Carcinoma, Urothelial, melanoma head and neck.

This is for all treatments of Keytruda -

Lung: 87.6% (n=254) of treatments were 8ml (200mg) 3-weekly, 12.4% (n=36) of treatments were 16ml (400mg) 6-weekly.

Renal: no treatments

Urothelial: 96.7% (n=1) of treatments were 8ml (200mg) 3-weekly, 3.3% (n=1) of treatments were 16ml (400mg) 6-weekly.

Melanoma: 100% (n=83) of treatments were 8ml (200mg) 3-weekly.